Spero Therapeutics Inc (SPRO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2026 | 03-2026 | 12-2025 | 09-2025 | 06-2025 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 50,774 | 56,129 | 40,265 | 48,616 | 31,194 |
| Receivables | 25 | 44 | 25,387 | 2,459 | 26,913 |
| TOTAL | $51,584 | $57,612 | $67,286 | $52,323 | $59,402 |
| Non-Current Assets | |||||
| Other Non-Current Assets | 1,182 | 1,409 | 1,633 | 1,847 | 2,717 |
| TOTAL | $1,182 | $1,409 | $1,633 | $1,847 | $2,717 |
| Total Assets | $52,766 | $59,021 | $68,919 | $54,170 | $62,119 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 155 | 217 | 693 | 1,395 | 780 |
| Accrued Expenses | 6,110 | 3,142 | 5,578 | 7,809 | 6,727 |
| TOTAL | $8,428 | $5,489 | $8,868 | $13,649 | $14,945 |
| Non-Current Liabilities | |||||
| Deferred Revenues | N/A | N/A | 258 | 2,383 | 5,431 |
| Other Non-Current Liabilities | 134 | 598 | 1,030 | 1,452 | 1,771 |
| TOTAL | $134 | $598 | $1,030 | $14,027 | $14,346 |
| Total Liabilities | $8,562 | $6,087 | $9,898 | $27,676 | $29,291 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 58,235 | 57,901 | 57,891 | 56,339 | 56,275 |
| Common Shares | 58 | 58 | 56 | 56 | 56 |
| Retained earnings | -467,821 | -458,269 | -451,066 | -482,586 | -475,204 |
| TOTAL | $44,204 | $52,934 | $59,021 | $26,494 | $32,828 |
| Total Liabilities And Equity | $52,766 | $59,021 | $68,919 | $54,170 | $62,119 |